Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
THT 2025: The SUMMIT Trial
Author(s): Barry Borlaug Added: 1 year ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Author(s): C Noah Nilsson , Mads Kristian Ersbøll , Finn Gustafsson Added: 1 year ago

Heart Failure
Tirzepatide Benefits in HFpEF Consistent Across Obesity Levels, SUMMIT Analysis Shows
Added: 8 months ago Source:  Radcliffe CVRM
A secondary analysis of the SUMMIT trial has found that the benefits of tirzepatide on reducing the risk of cardiovascular death or worsening heart failure (HF) are consistent across all levels of obesity in patients with heart failure with preserved ejection fraction (HFpEF).¹ However, patients with a higher baseline body mass index (BMI) experienced greater improvements in exercise capacity and… View more

Cardiovascular Kidney Metabolic

Heart Failure
Mineralocorticoid Receptor Antagonists in Heart Failure
Author(s): Rishi Sethi , Pravesh Vishwakarma , Akshyaya Pradhan Added: 1 year ago

MI/ACS

Heart Failure
Understanding the Role of GLP-1 RAs in the Treatment of HF
Author(s): Giovanni Battista Bonfioli , Matteo Pagnesi , Daniela Tomasoni , et al Added: 8 months ago

Cardiovascular Kidney Metabolic

Heart Failure
Effects of GLP-1 Receptor Agonists in Heart Failure Patients
Author(s): Anastasia Shchendrygina , Amina Rakisheva , Ilya Giverts , et al Added: 1 year ago

Heart Failure
AHA 24: The EMPEROR-Preserved Trial
Author(s): Andrew JS Coats Added: 1 year ago
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial.Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).EMPEROR… View more

Heart Failure
SGLTi and GLP-1 in HF
Author(s): Jose L Batista , Tracy Makuvire , Jonathan D Davis , et al Added: 11 months ago

Cardiovascular Kidney Metabolic

Heart Failure
Christian Besler practices in Leipzig, Germany. Besler is highly rated in 7 conditions, according to data. His top areas of expertise are Tricuspid Regurgitation, Heart Failure with Preserved Ejection Fraction HFpEF, Heart Failure, Heart Valve Repair, and Cardiac Ablation. Hisclinical researchconsists of co-authoring 95 peer-reviewed articles and participating in 4 clinical trials in the past… View more
Aldosterone and Potassium in Heart Failure
Author(s): Laibah Arshad Khan , Adeena Jamil , Stephen J Greene , et al Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic